UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

10 years of L-DOPA therapy of Parkinson's syndrome

Wiener Klinische Wochenschrift, 1971-04, Vol.83 (13), p.221

Birkmayer, W

1971

Volltextzugriff (PDF)

10 years of substitution therapy for neurodegenerative diseases using fetal neuron grafts: a positive outcome but with questions for the future

Journal de la Société de biologie, 2001, Vol.195 (1), p.51

Peschanski, M

2001

Volltextzugriff (PDF)

11 clinical trials that will shape medicine in 2022

Nature medicine, 2021-12, Vol.27 (12), p.2062-2064

Arnold, Carrie

2021

Volltextzugriff (PDF)

2,4 DNP improves motor function, preserves medium spiny neuronal identity, and reduces oxidative stress in a mouse model of Huntington's disease

Experimental neurology, 2017-07, Vol.293, p.83-90

2017

Volltextzugriff (PDF)

2-chloro-11(4'-methylpiperazino)-dibenzo-(b,f)(1,4)-oxazepine (Sum 3170), a new neuroleptic. Results of clinical testing

Arzneimittel-Forschung, 1970-07, Vol.20 (7), p.967

1970

Volltextzugriff (PDF)

2-Dimethylaminoethanol (deanol): a brief review of its clinical efficacy and postulated mechanism of action

Current therapeutic research, 1974-11, Vol.16 (11), p.1238

Re', O

1974

Volltextzugriff (PDF)

2-Dimethylaminoethanol (Deanol) in Huntington's chorea

Journal of neurology, neurosurgery and psychiatry, 1978-12, Vol.41 (12), p.1114-1118

1978

Volltextzugriff (PDF)

3-Hydroxyanthranilic Acid Delays Paralysis in Caenorhabditis elegans Models of Amyloid-Beta and Polyglutamine Proteotoxicity

Biomolecules (Basel, Switzerland), 2024-05, Vol.14 (5), p.599

2024

Volltextzugriff (PDF)

4-hydroxy tempo improves mitochondrial and neurobehavioral deficits in experimental model of Huntington's disease

Synapse (New York, N.Y.), 2015-03, Vol.69 (3), p.128-138

2015

Volltextzugriff (PDF)

48. In Vivo and In Situ Delivery of Huntingtin-Specific Single-Chain Fv Intrabody Genes as Therapeutic Agents for Huntington's Disease

Molecular therapy, 2004-05, Vol.9 (S1), p.S20-S21

2004

Volltextzugriff (PDF)

5,6,7 trihydroxy flavone armoured neurodegeneration caused by Quinolinic acid induced huntington’s like disease in rat striatum - reinstating the level of brain neurotrophins with special reference to cognitive-socio behaviour, biochemical and histopathological aspects

Neuroscience research, 2022-01, Vol.174, p.25-35

2022

Volltextzugriff (PDF)

5-hydroxytryptamine subtype 6 receptor modulators: a patent survey

Expert opinion on therapeutic patents, 2010-09, Vol.20 (9), p.1171-1196

2010

Volltextzugriff (PDF)

7,8-dihydroxyflavone ameliorates cognitive and motor deficits in a Huntington's disease mouse model through specific activation of the PLCγ1 pathway

Human molecular genetics, 2017-08, Vol.26 (16), p.3144-3160

2017

Volltextzugriff (PDF)

The A2A adenosine receptor rescues the urea cycle deficiency of Huntington's disease by enhancing the activity of the ubiquitin–proteasome system

Human molecular genetics, 2009-08, Vol.18 (16), p.2929-2942

2009

Volltextzugriff (PDF)

AAV-dominant negative tumor necrosis factor (DN-TNF) gene transfer to the striatum does not rescue medium spiny neurons in the YAC128 mouse model of Huntington's disease

PloS one, 2014-05, Vol.9 (5), p.e96544-e96544

2014

Volltextzugriff (PDF)

L-acetyl-carnitine in Huntington's disease: double-blind placebo controlled crossover study of drug effects on movement disorder and dementia

Movement disorders, 1990, Vol.5 (3), p.263

1990

Volltextzugriff (PDF)

Acetylcholine replacement therapy in the menagement of huntington's disease

The Western journal of medicine, 1981-11, Vol.135 (5), p.426

Corbascio, A N

1981

Volltextzugriff (PDF)

Action myoclonus in adult Huntington's disease

Rinshō shinkeigaku, 1992-07, Vol.32 (7), p.739

1992

Volltextzugriff (PDF)

Action of sulpiride on abnormal movements

Lille medical : journal de la Faculte de medecine et de pharmacie de l'Universite de Lille, 1972-01, Vol.17, p.Suppl 1:14

1972

Volltextzugriff (PDF)

Activating mitochondrial regulator PGC-1α expression by astrocytic NGF is a therapeutic strategy for Huntington's disease

Neuropharmacology, 2012-09, Vol.63 (4), p.719-732

2012

Volltextzugriff (PDF)

Activation and Regulation of Caspase-6 and Its Role in Neurodegenerative Diseases

Annual review of pharmacology and toxicology, 2015-01, Vol.55 (1), p.553-572

2015

Volltextzugriff (PDF)

Activation of alpha-7 nicotinic acetylcholine receptor by tropisetron mitigates 3-nitropropionic acid-induced Huntington's disease in rats: Role of PI3K/Akt and JAK2/NF-κB signaling pathways

Chemico-biological interactions, 2024-04, Vol.393, p.110957-110957, Article 110957

2024

Volltextzugriff (PDF)

Activation of AMPK-induced autophagy ameliorates Huntington disease pathology in vitro

Neuropharmacology, 2016-09, Vol.108, p.24-38

2016

Volltextzugriff (PDF)

Activation of NPY-Y2 receptors ameliorates disease pathology in the R6/2 mouse and PC12 cell models of Huntington's disease

Experimental neurology, 2018-04, Vol.302, p.112-128

2018

Volltextzugriff (PDF)

Activin A directs striatal projection neuron differentiation of human pluripotent stem cells

Development (Cambridge), 2015-04, Vol.142 (7), p.1375-1386

2015

Volltextzugriff (PDF)

1 – 25 von 2.312

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(2.067)
Mit Volltextzugriff
(1.581)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

12 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(1.906)
Life Sciences & Biomedicine
(1.792)
Humans
(1.787)
Huntington Disease - Drug Therapy
(1.459)
Animals
(1.093)
Neurosciences & Neurology
(906)
Huntington's Disease
(840)
Male
(798)
Female
(639)
Neurosciences
(636)
Disease Models, Animal
(507)
Middle Aged
(456)
Pharmacology & Pharmacy
(442)
Clinical Neurology
(434)
Huntington Disease - Metabolism
(433)
Adult
(430)
Mice
(429)
Neurology
(424)
Huntington Disease - Genetics
(402)
Biological And Medical Sciences
(361)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

MEDLINE
(2.185)
Ingenta
(1.100)
Journals@Ovid Ovid Full Text
(970)
EZB Free E-Journals
(780)
IngentaConnect Journals
(537)
Single Journals
(474)
Elsevier ScienceDirect Journals Complete
(458)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(344)
Wiley-Blackwell Journals
(285)
Springer journals
(233)
Wiley Online Library Full Collection 2018
(232)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(144)
Taylor & Francis Journals
(115)
Taylor & Francis
(96)
Nexis Uni
(94)
Nature Journals
(89)
Taylor & Francis Online
(82)
EBSCO_Psychology & Behavioral Sciences Collection
(69)
JSTOR All Journals
(63)
Oxford University Press Journals Current
(55)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

10 years of L-DOPA therapy of Parkinson's syndrome

10 years of substitution therapy for neurodegenerative diseases using fetal neuron grafts: a positive outcome but with questions for the future

11 clinical trials that will shape medicine in 2022

2,4 DNP improves motor function, preserves medium spiny neuronal identity, and reduces oxidative stress in a mouse model of Huntington's disease

2-chloro-11(4'-methylpiperazino)-dibenzo-(b,f)(1,4)-oxazepine (Sum 3170), a new neuroleptic. Results of clinical testing

2-Dimethylaminoethanol (deanol): a brief review of its clinical efficacy and postulated mechanism of action

2-Dimethylaminoethanol (Deanol) in Huntington's chorea

3-Hydroxyanthranilic Acid Delays Paralysis in Caenorhabditis elegans Models of Amyloid-Beta and Polyglutamine Proteotoxicity

4-hydroxy tempo improves mitochondrial and neurobehavioral deficits in experimental model of Huntington's disease

48. In Vivo and In Situ Delivery of Huntingtin-Specific Single-Chain Fv Intrabody Genes as Therapeutic Agents for Huntington's Disease

5,6,7 trihydroxy flavone armoured neurodegeneration caused by Quinolinic acid induced huntington’s like disease in rat striatum - reinstating the level of brain neurotrophins with special reference to cognitive-socio behaviour, biochemical and histopathological aspects

5-hydroxytryptamine subtype 6 receptor modulators: a patent survey

7,8-dihydroxyflavone ameliorates cognitive and motor deficits in a Huntington's disease mouse model through specific activation of the PLCγ1 pathway

The A2A adenosine receptor rescues the urea cycle deficiency of Huntington's disease by enhancing the activity of the ubiquitin–proteasome system

AAV-dominant negative tumor necrosis factor (DN-TNF) gene transfer to the striatum does not rescue medium spiny neurons in the YAC128 mouse model of Huntington's disease

L-acetyl-carnitine in Huntington's disease: double-blind placebo controlled crossover study of drug effects on movement disorder and dementia

Acetylcholine replacement therapy in the menagement of huntington's disease

Action myoclonus in adult Huntington's disease

Action of sulpiride on abnormal movements

Activating mitochondrial regulator PGC-1α expression by astrocytic NGF is a therapeutic strategy for Huntington's disease

Activation and Regulation of Caspase-6 and Its Role in Neurodegenerative Diseases

Activation of alpha-7 nicotinic acetylcholine receptor by tropisetron mitigates 3-nitropropionic acid-induced Huntington's disease in rats: Role of PI3K/Akt and JAK2/NF-κB signaling pathways

Activation of AMPK-induced autophagy ameliorates Huntington disease pathology in vitro

Activation of NPY-Y2 receptors ameliorates disease pathology in the R6/2 mouse and PC12 cell models of Huntington's disease

Activin A directs striatal projection neuron differentiation of human pluripotent stem cells

Suchergebnisse filtern